Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhTATE
- Development stage
- Unknown
- Lead developer
- Scintomics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
rhTATE is a somatostatin receptor (SSTR)-targeted radiohybrid radiopharmaceutical developed by Scintomics GmbH in collaboration with the Technical University of Munich. It is based on the proprietary radiohybrid (rh) platform, which incorporates a silicon-fluoride acceptor (SiFA) moiety. This technology allows for the labeling of the same peptide ligand with either a diagnostic isotope (typically Fluorine-18) or a therapeutic isotope (such as Lutetium-177) without altering the molecule's biological properties or binding affinity. rhTATE specifically targets the somatostatin receptor type 2 (SSTR2), which is highly overexpressed in various neuroendocrine tumors (NETs). In its diagnostic application, [18F]rhTATE is utilized for positron emission tomography (PET) imaging to detect, stage, and monitor NETs, offering high-resolution imaging and favorable pharmacokinetics compared to traditional gallium-68 labeled somatostatin analogues.
- Other names
- radiohybrid-TATE18F-rhTATESiTATE
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on rhTATE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhTATE.